AGIO Agios Pharmaceuticals Inc.

65.82
-1.04  -2%
Previous Close 66.86
Open 67.15
Price To book 6.26
Market Cap 3185108389
Shares 48,391,194
Volume 322,503
Short Ratio 13.23
Av. Daily Volume 473,224

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016 with updated data released at EHA June 24, 2017. Pivotal trial to commence 1H 2018.
AG-348
Pyruvate kinase deficiency
Phase 3 to be initiated 2Q 2017.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of April 2017.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. ETFs with exposure to Agios Pharmaceuticals, Inc. : September 18, 2017
  2. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  3. Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17
  4. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
  5. Agios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017
  6. 5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
  7. Agios Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating
  8. Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : August 28, 2017
  9. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017
  10. Edited Transcript of AGIO earnings conference call or presentation 8-Aug-17 12:00pm GMT
  11. IHS Markit Score Update: Drop in demand for ETFs holding Agios Pharmaceuticals Inc is a negative sign for its shares
  12. Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y
  13. Agios Pharmaceuticals reports 2Q loss
  14. Agios Reports Second Quarter 2017 Financial Results
  15. 4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
  16. Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
  17. Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?

SEC Filings

  1. UPLOAD [Cover] - SEC-generated letter
  2. CORRESP [Cover] - Correspondence
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014141
  4. 8-K - Current report 171013247
  5. UPLOAD [Cover] - SEC-generated letter
  6. 8-K - Current report 17997210
  7. 8-K - Current report 17928885
  8. 8-K - Current report 17911291
  9. 8-K - Current report 17894410
  10. 8-K - Current report 17881352